Muutke küpsiste eelistusi

E-raamat: Privileged Scaffolds in Drug Discovery

Edited by (College of Life Sciences and Medicine, Zhejiang Sci-Tech), Edited by (School of Chinese Materia Medica, Shenyang Pharmaceutical University, China), Edited by (Professor of Medicinal Chemistry, School of Pharmaceutical Sciences, Zhengzhou University, China)
  • Formaat: PDF+DRM
  • Ilmumisaeg: 19-Jul-2023
  • Kirjastus: Academic Press Inc
  • Keel: eng
  • ISBN-13: 9780443186127
Teised raamatud teemal:
  • Formaat - PDF+DRM
  • Hind: 279,82 €*
  • * hind on lõplik, st. muud allahindlused enam ei rakendu
  • Lisa ostukorvi
  • Lisa soovinimekirja
  • See e-raamat on mõeldud ainult isiklikuks kasutamiseks. E-raamatuid ei saa tagastada.
  • Formaat: PDF+DRM
  • Ilmumisaeg: 19-Jul-2023
  • Kirjastus: Academic Press Inc
  • Keel: eng
  • ISBN-13: 9780443186127
Teised raamatud teemal:

DRM piirangud

  • Kopeerimine (copy/paste):

    ei ole lubatud

  • Printimine:

    ei ole lubatud

  • Kasutamine:

    Digitaalõiguste kaitse (DRM)
    Kirjastus on väljastanud selle e-raamatu krüpteeritud kujul, mis tähendab, et selle lugemiseks peate installeerima spetsiaalse tarkvara. Samuti peate looma endale  Adobe ID Rohkem infot siin. E-raamatut saab lugeda 1 kasutaja ning alla laadida kuni 6'de seadmesse (kõik autoriseeritud sama Adobe ID-ga).

    Vajalik tarkvara
    Mobiilsetes seadmetes (telefon või tahvelarvuti) lugemiseks peate installeerima selle tasuta rakenduse: PocketBook Reader (iOS / Android)

    PC või Mac seadmes lugemiseks peate installima Adobe Digital Editionsi (Seeon tasuta rakendus spetsiaalselt e-raamatute lugemiseks. Seda ei tohi segamini ajada Adober Reader'iga, mis tõenäoliselt on juba teie arvutisse installeeritud )

    Seda e-raamatut ei saa lugeda Amazon Kindle's. 

Privileged Scaffolds in Drug Discovery is the most complete and up-to-date work in the area. Covering a wide range of privileged structures, it is a perfect reference for scientists involved in targeted drug development.

The editors recruited epserts from several prestigious Chinese institutions to cover the areas of antiviral drugs, chalcone, pyrimidine, (benz)imidazoles, natural product-derived privileged scaffolds, N-Sulfonyl carboxamides, kinase inhibitors, antitumor molecules, antineurodegenerative drugs, triazoles, oxazolidinone, indole and indoline scaffolds, tigliane diterpenoids, peptide and peptide-based drugs, quassinoids, and others including pseudonatural products, macrocycles, stable peptides and peptidomimetics. The book also explores scaffolds in drug molecules approved in recent years.

Privileged Scaffolds in Drug Discovery is a complete reference for researchers in drug discovery and organic synthesis, in academic and corporate settings, who are investigating privileged structures upon which to base new drugs. Researchers in medicinal chemistry and chemical biology will also find the contents of this book valuable.

  • Provides wide coverage of privileged scaffolds in new drug discovery
  • Includes complex and diverse natural product scaffolds
  • Covers applications to peptides and peptide-based drugs
1. Thiazole, a privileged scaffold in new drug discovery
2. Chalcone:
Diverse biological activities and structure-activity relationships
3.
Privileged chalcone scaffolds in drug discovery
4. The N-sulfonyl carboxamide
moiety as a privileged structure in approved drugs
5. Scaffolds in cytotoxic
drugs and novel antitumor molecules interacting with nucleic acids
6.
Triazoles: a privileged scaffold in drug design and novel drug discovery
7.
Oxazolidinone scaffolds in drug discovery and development
8. Indole and
indoline scaffolds in drug discovery
9. Cyanopyridine as a privileged
scaffold in drug discovery
10. Indazole as privileged scaffold in drug
discovery
11. (Benz)imidazoles: privileged scaffolds in medicinal chemistry
12. Tranylcypromine (TCP): a privileged scaffold for designing histone lysine
demethylase 1 inhibitors
13. Applications of piperazine scaffold in drug
design
14. Thiols as a privileged scaffold against metallo--lactamases
15.
Tetrahydro--carboline scaffold in drug discovery
16. Benzoxaborole: a
privileged scaffold for drug discovery
17. Privileged scaffolds in
anti-diabetic drug discovery
18. Authentic HIV-1 integrase inhibitors for the
treatment of HIV-1/AIDS
19. 2-Aminopyrimidine: a privileged scaffold in
kinase drug discovery
20. Alzheimers disease therapeutics: current
strategies and future directions
21. Sulfonyl fluorides as warheads in drug
discovery
22. ,-Bifunctionalized carbonyl compounds as privileged motifs in
drug discovery and their synthetic protocols
23. Diarylpyrimidines and
related analogs as antiviral agents
24. Organic synthetic methodology-based
new scaffold in drug discovery
25. Natural resource of anti-human
immunodeficiency virus leading compounds: tigliane diterpenoids
26.
Biological phenethyl glycosides from plants
27. Triterpenoids and saponins in
drug discovery
28. Casbene-derived diterpenoids
29. Quassinoids:
phytochemistry and antitumor prospect
30. Structural diversity, biosynthesis,
and biological functions of meroterpenoids from microbial metabolites
31.
Glucocorticoid compounds in drug discovery by targeting glucocorticoid
receptor protein
32. Peptide and peptide-based drugs
33. Stapled peptides for
new drug discovery
34. Current status and trends in research and development
of polypeptide drugs
35. Unique opportunities of metal scaffolds in drug
design
36. N-Heterocyclic carbene as privileged scaffold in medicinal
inorganic chemistry
37. Selenium-containing heterocycles
38. Computational
methods for scaffold hopping
Professor Bin Yu obtained his PhD degree from Zhengzhou University and University of Cambridge and currently is a professor of medicinal chemistry at School of Pharmaceutical Sciences, Zhengzhou University. His research interests focus on chemistry driven drug discovery for novel therapeutics. To date, he has published over 120 papers in international high-impact peer-reviewed journals including Journal of Medicinal Chemistry, Organic Letters, Pharmacology & Therapeutics, Journal of Hematology & Oncology, Drug Discovery Today, Acta Pharmaceutica Sinica B, etc., 10 of them were published in journal with impact factor (IF) >10. Professor Ning Li is the associate dean of Chinese Materia Medica of Shenyang Pharmaceutical University, the "Youth talent" of Liao Ning Revitalization Talents Program, the "Talent of Hundred level" of Liaoning Bai Qian Wan Talents Program, the "Leading talent" of both Shenyang High-Level Talent Program and Xinjiang Uygur Autonomous Region. She has focused on the research of chemoprevention of critical diseases, especially the neurodegenerative disease and cancer, through post-transcriptional mechanism on the perspective view of preventive treatment strategy of the Traditional Chinese theory. She has hosted seven projects of National Natural Science Foundation of China and published more than 120 SCI papers on famous academic journals, born several prizes like the "First Prize of Provincial Science and technology progress award", and obtained the authorization of 20 invention patents. Professor Caiyun Fu obtained her PhD degree from Lanzhou university and currently is a professor of biology and deputy director of the College of Life Sciences and Medicine, director of the Research Institute for Polypeptide and Protein Pharmaceutical Products, Zhejiang Sci-Tech University. Her research interests focus on screening and identification of tumor targets and exploration of targeted intervention and developing new drugs of peptides by synthetic biology. To date she has published 34 academic papers as corresponding author or first author in international high-impact peer-reviewed journals, including Proceedings of the National Academy of Sciences of the United States of America, Advanced Science, Journal of the American Chemical Society, Angewandte Chemie International Edition, Signal Transduction and Targeted Therapy, etc